• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Kezar Life Sciences Inc. (Amendment)

    8/17/23 5:14:58 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZR alert in real time by email
    SC 13D/A 1 d524248dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Kezar Life Sciences, Inc.

    (Name of issuer)

    Common Stock, par value $0.001 per share

    (Title of class of securities)

    49372L100

    (CUSIP number)

    Morningside Venture Investments Limited

    C/O THC Management Services S.A.M.

    2nd Floor, Le Prince De Galles

    3-5 Avenue Des Citronniers

    Monaco, MC 98000

    011-377-97-97-47-37

    with a copy to:

    Morningside Technology Advisory, LLC

    Attn: Stephanie O’Brien, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

    (Name, address and telephone number of person authorized to receive notices and communications)

    August 15, 2023

    (Date of event which requires filing of this statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 49372L100

     

      (1)    

      Names of reporting persons

     

      Morningside Venture Investments Limited

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      WC

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or place of organization

     

      British Virgin Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      0

         (8)   

      Shared voting power

     

      1,947,993

         (9)   

      Sole dispositive power

     

      0

       (10)   

      Shared dispositive power

     

      1,947,993

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      1,947,993

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

      ☐

    (13)  

      Percent of class represented by amount in Row (11)

     

      2.68% (1)

    (14)  

    Type of reporting person (see instructions)

     

      CO

     

    (1)

    Based on 72,692,963 shares of Common Stock outstanding as of August 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 10, 2023.

     

    2


    CUSIP No. 49372L100

     

      (1)    

      Names of reporting persons

     

      Frances Anne Elizabeth Richard

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      AF

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or place of organization

     

      United Kingdom

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      0

         (8)   

      Shared voting power

     

      1,947,993

         (9)   

      Sole dispositive power

     

      0

       (10)   

      Shared dispositive power

     

      1,947,993

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      1,947,993

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

      ☐

    (13)  

      Percent of class represented by amount in Row (11)

     

      2.68% (1)

    (14)  

    Type of reporting person (see instructions)

     

      IN

     

    (1)

    Based on 72,692,963 shares of Common Stock outstanding as of August 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.

     

    3


    CUSIP No. 49372L100

     

      (1)    

      Names of reporting persons

     

      Jill Marie Franklin

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      AF

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or place of organization

     

      United Kingdom

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      0

         (8)   

      Shared voting power

     

      1,947,993

         (9)   

      Sole dispositive power

     

      0

       (10)   

      Shared dispositive power

     

      1,947,993

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      1,947,993

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

      ☐

    (13)  

      Percent of class represented by amount in Row (11)

     

      2.68% (1)

    (14)  

    Type of reporting person (see instructions)

     

      IN

     

    (1)

    Based on 72,692,963 shares of Common Stock outstanding as of August 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.

     

    4


    CUSIP No. 49372L100

     

      (1)    

      Names of reporting persons

     

      Peter Stuart Allenby Edwards

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      AF

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or place of organization

     

      United Kingdom

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      0

         (8)   

      Shared voting power

     

      1,947,993

         (9)   

      Sole dispositive power

     

      0

       (10)   

      Shared dispositive power

     

      1,947,993

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      1,947,993

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

      ☐

    (13)  

      Percent of class represented by amount in Row (11)

     

      2.68% (1)

    (14)  

    Type of reporting person (see instructions)

     

      IN

     

    (1)

    Based on 72,692,963 shares of Common Stock outstanding as of August 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.

     

    5


    CUSIP No. 49372L100

     

      (1)    

      Names of reporting persons

     

      Cheung Ka Ho

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      AF

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or place of organization

     

      Hong Kong

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      0

         (8)   

      Shared voting power

     

      1,947,993

         (9)   

      Sole dispositive power

     

      0

       (10)   

      Shared dispositive power

     

      1,947,993

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      1,947,993

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

      ☐

    (13)  

      Percent of class represented by amount in Row (11)

     

      2.68% (1)

    (14)  

    Type of reporting person (see instructions)

     

      IN

     

    (1)

    Based on 72,692,963 shares of Common Stock outstanding as of August 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.

     

    6


    CUSIP No. 49372L100

     

      (1)    

      Names of reporting persons

     

      Equal Talent Investments Limited

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      WC

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or place of organization

     

      British Virgin Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      6,254,545

         (8)   

      Shared voting power

     

      0

         (9)   

      Sole dispositive power

     

      6,254,545

       (10)   

      Shared dispositive power

     

      0

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      6,254,545

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

      ☐

    (13)  

      Percent of class represented by amount in Row (11)

     

      8.60% (1)

    (14)  

    Type of reporting person (see instructions)

     

      CO

     

    (1)

    Based on 72,692,963 shares of Common Stock outstanding as of August 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.

     

    7


    CUSIP No. 49372L100

     

      (1)    

      Names of reporting persons

     

      Suk Ying Pauli Ng

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☒        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      AF

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      (6)  

      Citizenship or place of organization

     

      Hong Kong

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      6,254,545

         (8)   

      Shared voting power

     

      0

         (9)   

      Sole dispositive power

     

      6,254,545

       (10)   

      Shared dispositive power

     

      0

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      6,254,545

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

      ☐

    (13)  

      Percent of class represented by amount in Row (11)

     

      8.60% (1)

    (14)  

    Type of reporting person (see instructions)

     

      IN

     

    (1)

    Based on 72,692,963 shares of Common Stock outstanding as of August 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.

     

    8


    CUSIP No. 49372L100

     

    Item 1.

    Security and Issuer.

    This Amendment No. 3 amends and supplements the Schedule 13D/A filed by the Reporting Persons (as defined in Item 2 below) on February 16, 2021 (the “Schedule 13D/A”) and relates to their beneficial ownership interest in the common stock, par value $0.001 per share (the “Common Stock”), of Kezar Life Sciences, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive office of the Issuer is 4000 Shoreline Court, Suite 300, South San Francisco, California 94080. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Except as otherwise provided herein, each Item of the Schedule 13D/A remains unchanged.

     

    Item 2.

    Identity and Background.

    Item 2(b) is hereby amended in part as follows:

     

      (b)

    The business address of each of the Reporting Persons is:

     

      (i)

    With respect to Morningside Venture Investments Limited (“MVIL”), Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung:

    c/o THC Management Services S.A.M.,

    2nd Floor, Le Prince De Galles

    3-5 Avenue Des Citronniers

    MC 98000, Monaco

    With copies to:

    Morningside Technology Advisory, LLC

    Attn: Stephanie O’Brien, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

    Springfield Financial Advisory Limited

    Attn: : Investment Administration Department

    22nd Floor Hang Lung Centre

    2-20 Paterson Street

    Causeway Bay, Hong Kong

     

      (ii)

    With respect to Equal Talent Investments Limited (“ETIL”) and Ms. Ng:

    c/o THC Management Services S.A.M.,

    2nd Floor, Le Prince De Galles

    3-5 Avenue Des Citronniers

    MC 98000, Monaco

    With copies to:

    Morningside Technology Advisory, LLC

    Attn: Stephanie O’Brien, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

    Springfield Financial Advisory Limited

    Attn: : Investment Administration Department

    22nd Floor Hang Lung Centre

    2-20 Paterson Street

    Causeway Bay, Hong Kong

     

    9


    CUSIP No. 49372L100

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    Item 3 is hereby supplemented as follows:

    On August 15, 2023, MVIL donated an aggregate of 3,500,000 shares of Common Stock to a 501(c)(3) organization.

    On October 18, 2022, MVIL donated an aggregate of 120,000 shares of Common Stock to certain 501(c)(3) organizations.

    Between October 3, 2022 and February 6, 2023, MVIL sold an aggregate of 541,059 shares of Common Stock (See item 5(c) below).

     

    Item 5.

    Interest in Securities of the Issuer.

    Item 5 is hereby supplemented in its entirety as follows:

    The aggregate percentage of Common Stock reported beneficially owned by each person named herein is determined in accordance with SEC rules and is based upon 72,692,963 shares of Common Stock outstanding as of August 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023. The applicable SEC rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities.

     

    A.

    Morningside Venture Investments Limited

     

      (a)

    As of the date hereof, MVIL beneficially owned 1,947,993 shares of Common Stock, representing a beneficial ownership of approximately 2.68% of the Common Stock. All such shares are directly held by MVIL.

     

    (b)   1. Sole power to vote or direct vote:

         -0-  

    2. Shared power to vote or direct vote:

         1,947,993  

    3. Sole power to dispose or direct the disposition:

         -0-  

    4. Shared power to dispose or direct the disposition:

         1,947,993  

     

    B.

    Frances Anne Elizabeth Richard

     

      (a)

    As of the date hereof, Ms. Richard beneficially owned 1,947,993 shares of Common Stock, representing a beneficial ownership of approximately 2.68% of the Common Stock. All such shares are directly held by MVIL. Ms. Richard disclaims any personal beneficial ownership of such Common Stock.

     

    (b)   1. Sole power to vote or direct vote:

         -0-  

    2. Shared power to vote or direct vote:

         1,947,993  

    3. Sole power to dispose or direct the disposition:

         -0-  

    4. Shared power to dispose or direct the disposition:

         1,947,993  

     

    C.

    Jill Marie Franklin

     

      (a)

    As of the date hereof, Ms. Franklin beneficially owned 1,947,993 shares of Common Stock, representing a beneficial ownership of approximately 2.68% of the Common Stock. All such shares are directly held by MVIL. Ms. Franklin disclaims any personal beneficial ownership of such Common Stock.

     

    (b)   1. Sole power to vote or direct vote:

         -0-  

    2. Shared power to vote or direct vote:

         1,947,993  

    3. Sole power to dispose or direct the disposition:

         -0-  

    4. Shared power to dispose or direct the disposition:

         1,947,993  

     

    10


    CUSIP No. 49372L100

     

    D.

    Peter Stuart Allenby Edwards

     

      (a)

    As of the date hereof, Mr. Edwards beneficially owned 1,947,993 shares of Common Stock, representing a beneficial ownership of approximately 2.68% of the Common Stock. All such shares are directly held by MVIL. Mr. Edwards disclaims any personal beneficial ownership of such Common Stock.

     

    (b)   1. Sole power to vote or direct vote:

         -0-  

    2. Shared power to vote or direct vote:

         1,947,993  

    3. Sole power to dispose or direct the disposition:

         -0-  

    4. Shared power to dispose or direct the disposition:

         1,947,993  

     

    E.

    Cheung Ka Ho

     

      (a)

    As of the date hereof, Mr. Cheung beneficially owned 1,947,993 shares of Common Stock, representing a beneficial ownership of approximately 2.68% of the Common Stock. All such shares are directly held by MVIL. Mr. Cheung disclaims any personal beneficial ownership of such Common Stock.

     

    (b)   1. Sole power to vote or direct vote:

         -0-  

    2. Shared power to vote or direct vote:

         1,947,993  

    3. Sole power to dispose or direct the disposition:

         -0-  

    4. Shared power to dispose or direct the disposition:

         1,947,993  

     

    F.

    Equal Talent Investments Limited

     

      (a)

    As of the date hereof, ETIL beneficially owned 6,254,545 shares of Common Stock, representing a beneficial ownership of approximately 8.60% of the Common Stock. All such shares are directly held by ETIL.

     

    (b)   1. Sole power to vote or direct vote:

         6,254,545  

    2. Shared power to vote or direct vote:

         -0-  

    3. Sole power to dispose or direct the disposition:

         6,254,545  

    4. Shared power to dispose or direct the disposition:

         -0-  

     

    G.

    Suk Ying Pauli Ng

     

      (a)

    As of the date hereof, Ms. Ng beneficially owned 6,254,545 shares of Common Stock, representing a beneficial ownership of approximately 8.60% of the Common Stock. All such shares are beneficially owned by ETIL. Ms. Suk disclaims any personal beneficial ownership of such Common Stock.

     

    (b)   1. Sole power to vote or direct vote:

         6,254,545  

    2. Shared power to vote or direct vote:

         -0-  

    3. Sole power to dispose or direct the disposition:

         6,254,545  

    4. Shared power to dispose or direct the disposition:

         -0-  

     

    11


    CUSIP No. 49372L100

     

      Item 5(c)

    Set out below are details of the sales of Common Stock shares carried out by MVIL between October 3, 2022 and February 6, 2023:

     

    Date of transaction

       Entity making
    sale
         Price      Number of shares sold      Nature of the transaction  

    10/3/2022

         MVIL      $ 8.78        28,700        Open Market Sale  

    10/4/2022

         MVIL      $ 8.82        3,612        Open Market Sale  

    12/29/2022

         MVIL      $ 7.1        25,000        Open Market Sale  

    1/3/2023

         MVIL      $ 7.1        500        Open Market Sale  

    1/4/2023

         MVIL      $ 7.17        30,000        Open Market Sale  

    1/5/2023

         MVIL      $ 6.97        12,162        Open Market Sale  

    1/6/2023

         MVIL      $ 6.89        3000        Open Market Sale  

    1/12/2023

         MVIL      $ 6.77        5,000        Open Market Sale  

    1/13/2023

         MVIL      $ 7.15        1,971        Open Market Sale  

    1/17/2023

         MVIL      $ 6.79        6,114        Open Market Sale  

    1/23/2023

         MVIL      $ 6.81        80,000        Open Market Sale  

    1/24/2023

         MVIL      $ 6.98        80,000        Open Market Sale  

    1/25/2023

         MVIL      $ 6.85        50,000        Open Market Sale  

    1/30/2023

         MVIL      $ 6.91        30,000        Open Market Sale  

    1/31/2023

         MVIL      $ 7.08        30,000        Open Market Sale  

    2/1/2023

         MVIL      $ 6.95        40,000        Open Market Sale  

    2/2/2023

         MVIL      $ 7.19        50,000        Open Market Sale  

    2/3/2023

         MVIL      $ 7.15        25,000        Open Market Sale  

    2/6/2023

         MVIL      $ 6.88        40,000        Open Market Sale  

    Total:

         —          —          541,059        —    

     

      (d)

    Not applicable.

     

      (e)

    Not applicable.

     

    Item 7.

    Material to be Filed as Exhibits.

    The following documents are filed as Exhibits to this statement:

     

    Exhibit
    Number

      

    Exhibit Description

    99.1    Joint Filing Agreement

     

    12


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement listed on Exhibit 99.1 hereto.

    Dated: August 17, 2023

     

    MORNINGSIDE VENTURE INVESTMENTS LIMITED
    By:  

    /s/ Frances Anne Elizabeth Richard

      Frances Anne Elizabeth Richard, Director

    /s/ Frances Anne Elizabeth Richard

    Frances Anne Elizabeth Richard

    /s/ Jill Marie Franklin

    Jill Marie Franklin

    /s/ Peter Stuart Allenby Edwards

    Peter Stuart Allenby Edwards

    /s/ Cheung Ka Ho

    Cheung Ka Ho
    EQUAL TALENT INVESTMENTS LIMITED
    By:  

    /s/ Suk Ying Pauli Ng

      Suk Ying Pauli Ng, Director

    /s/ Suk Ying Pauli Ng

    Suk Ying Pauli Ng

     

    Get the next $KZR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KZR

    DatePrice TargetRatingAnalyst
    10/17/2025$7.00Buy → Hold
    Jefferies
    10/17/2025Outperform → Mkt Perform
    William Blair
    8/11/2023$4.00Overweight → Equal Weight
    Wells Fargo
    3/16/2023Outperform → Mkt Perform
    William Blair
    12/8/2021$19.00Overweight
    Wells Fargo
    11/16/2021$12.00 → $20.00Buy
    HC Wainwright & Co.
    7/20/2021$14.00Buy
    JonesTrading
    More analyst ratings

    $KZR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kezar Life Sciences downgraded by Jefferies with a new price target

    Jefferies downgraded Kezar Life Sciences from Buy to Hold and set a new price target of $7.00

    10/17/25 8:25:43 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by William Blair

    William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

    10/17/25 8:25:32 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00

    8/11/23 7:45:02 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory AIH. As part of the briefing package submitted to the FDA, Kezar submitt

    1/9/26 6:01:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Reports Third Quarter 2025 Financial Results

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder value. Kezar has retained TD Cowen to support it with the

    11/12/25 4:01:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the completed Phase 2a PORTOLA clinical trial in patients with autoimmune hepatitis (AIH) at The Liver Meeting 2025 held by the American Association for the Study of Liver Disease (AASLD) and taking place November 7-11, in Washington, DC. The presentation details are as follows: Oral Presentation Title: Zetomipzomib, a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrates Steroid Sparing Biochemical Remission in Patients with Relapsed or Insufficiently Responding Auto

    11/7/25 7:01:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    SEC Filings

    View All

    SEC Form 10-Q filed by Kezar Life Sciences Inc.

    10-Q - Kezar Life Sciences, Inc. (0001645666) (Filer)

    11/12/25 4:21:30 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

    11/12/25 4:07:21 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

    8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

    11/7/25 4:21:15 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Schiller Mark C. sold $2,401 worth of shares (561 units at $4.28), decreasing direct ownership by 17% to 2,739 units (SEC Form 4)

    4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

    7/3/25 4:15:27 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Corporate Controller Chiang Pichi Luo sold $1,130 worth of shares (264 units at $4.28), decreasing direct ownership by 9% to 2,711 units (SEC Form 4)

    4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

    7/3/25 4:15:28 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Development Officer To Zung Phuong

    4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

    7/1/25 5:25:28 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Financials

    Live finance-specific insights

    View All

    Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

    Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

    3/25/25 7:30:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. After careful consideration and with the a

    10/17/24 8:35:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

    Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. "The goal of Kezar's R&D Day is to set expectations for 2023, provide updates on our two clinical assets, and highlight the productivity from our Discovery team. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details," said John Fowler, Kezar's

    3/13/23 7:00:00 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Leadership Updates

    Live Leadership Updates

    View All

    Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

    Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026 Co-Founder and Board Director, Christopher Kirk, PhD, appointed as Chief Executive Officer   Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment

    10/3/23 4:10:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

    Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer Cash, cash equivalents and marketable securities totaled $306.8 million as of June 30, 2022 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. "The second quarter was tremendously productive for Kezar, during which we achieved key clinical milestone

    8/11/22 4:01:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Kezar Life Sciences, Inc., (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company's Chief Business Officer, the Compensation Committee of the company's Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purchase 200,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar's common stock on August 1, 2022. In addition, the Compensation Committee of the company's Board of Directors granted

    8/3/22 4:30:00 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Kezar Life Sciences Inc.

    SC 13D - Kezar Life Sciences, Inc. (0001645666) (Subject)

    10/8/24 4:20:17 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kezar Life Sciences Inc.

    SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

    7/8/24 4:32:39 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kezar Life Sciences Inc. (Amendment)

    SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

    2/14/24 6:47:29 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care